{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}],"title":"Participants with all-causality TEAEs leading to death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Participants with treatment-related TEAEs leading to death"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"description":"TEAEs were those events with onset dates occurring during the on-treatment period.","groups":[{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 1 mg as a subcutaneous (SC) administration every 2 weeks (Q2W) for a maximum duration of 10.9 months.","id":"OG000","title":"PF-07209960 1 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 3 mg as a SC administration Q2W for a maximum duration of 5.1 months.","id":"OG001","title":"PF-07209960 3 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 10 mg as a SC administration Q2W for a maximum duration of 3.4 months.","id":"OG002","title":"PF-07209960 10 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 15 mg as a SC administration Q2W for a maximum duration of 5.8 months.","id":"OG003","title":"PF-07209960 15 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 20 mg as a SC administration Q2W for a maximum duration of 13.6 months.","id":"OG004","title":"PF-07209960 20 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 30 mg as a SC administration Q2W for a maximum duration of 12.6 months.","id":"OG005","title":"PF-07209960 30 mg SC"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis set included all enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From start of the treatment until a minimum of 90 days after the last dose of study intervention (maximum up to 16.6 months)","title":"Number of Participants With TEAEs Leading to Death","type":"PRIMARY","unitOfMeasure":"Participants"}